Compass Therapeutics Investor Presentation Deck

How Does CTX-009 Data Compared to Other BTC Studies? FOLFOX (ABC-06) 1 Gem/Cis 2 1L Only 2L Parameter ORR OS PFS Any AE Gr 3/4 AEs Deaths (as Gr 5) AEs leading to discontinuation COMPASS THERAPEUTICS CTX-009 Mixed 2L and 3L N=24 37.5% [64% 2L; 15% 3L] 12.5 m 9.4 m 100% 92% 1 (4%) 25% N=81 5% 6.2 m 4.0 m 99% 60% 10 (12%) ~ 12% 1. Lamarca D, Lancet Oncol 2021; March 30 2. Valle, J. et al., N ENGL J MED, 362; 14 Apr 8, 2010, p. 1273 Oh, D. et al., ESMO Poster 56P 2022 3. N=204 26% 11.7 m 8.0 m 55% 71% 17 (8%) 10% Gem/Cis + Durv 3 Only 1L N=341 26.7% 12.9 m 7.2 m 99.4% 74% 13 (4%) 13% 22

View entire presentation